Improved cancer immunotherapy strategies by nanomedicine

Guo, Shuai; Feng, Jie; Li, Zongheng; Yang, Su‐Geun; Qiu, Xiaozhong; Xu, Yikai; Shen, Zheyu

doi:10.1002/wnan.1873

Cited by 8 publications

(4 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This therapy is based on the use of compounds that can activate or boost the immune response to kill cancer cells. These compounds include immune checkpoint inhibitors (ICIs) (e.g., PD1/PD-L1), cytokines (e.g., IL-2, TGF-β1, IL-12 and IL-15), chimeric antigen receptor (CAR)-T cells and monoclonal antibodies [ 72 ]. Although immunotherapy significantly improves tumor progression and patient survival, several patients do not show any beneficial effects from this therapy [ 73 ].…”

Section: Cd93 In Diseasesmentioning

confidence: 99%

Role of CD93 in Health and Disease

Tossetta

Piani

Borghi

et al. 2023

Cells

View full text Add to dashboard Cite

CD93 (also known as complement protein 1 q subcomponent receptor C1qR1 or C1qRp), is a transmembrane glycoprotein encoded by a gene located on 20p11.21 and composed of 652 amino acids. CD93 can be present in two forms: soluble (sCD93) and membrane-bound (CD93). CD93 is mainly expressed on endothelial cells, where it plays a key role in promoting angiogenesis both in physiology and disease, such as age-related macular degeneration and tumor angiogenesis. In fact, CD93 is highly expressed in tumor-associated vessels and its presence correlates with a poor prognosis, poor immunotherapy response, immune cell infiltration and high tumor, node and metastasis (TNM) stage in many cancer types. CD93 is also expressed in hematopoietic stem cells, cytotrophoblast cells, platelets and many immune cells, i.e., monocytes, neutrophils, B cells and natural killer (NK) cells. Accordingly, CD93 is involved in modulating important inflammatory-associated diseases including systemic sclerosis and neuroinflammation. Finally, CD93 plays a role in cardiovascular disease development and progression. In this article, we reviewed the current literature regarding the role of CD93 in modulating angiogenesis, inflammation and tumor growth in order to understand where this glycoprotein could be a potential therapeutic target and could modify the outcome of the abovementioned pathologies.

show abstract

Section: Cd93 In Diseasesmentioning

confidence: 99%

Role of CD93 in Health and Disease

Tossetta

Piani

Borghi

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Similar to the rationale behind using deep hyperthermia, CTLA-4 inhibitors might also contribute to reducing the side effects of chemotherapy by potentially requiring lower doses of chemotherapeutic agents due to the enhanced immune response ( 36 , 37 ). Since hyperthermia can enhance the efficacy of chemotherapy and targeted therapies, there’s potential to explore how it interacts with CTLA-4 inhibitors ( 38 , 39 ). Hyperthermia may alter the tumor microenvironment in a way that makes immunotherapy more effective ( 40 ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study

Han,

Cui,

Sun

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThis study aimed to explore the clinical efficacy and safety of a modified FOLFOX6 (oxaliplatin + leucovorin + 5-fluorouracil) plus bevacizumab regimen after deep hyperthermia in advanced colorectal cancer.MethodsA total of 80 colorectal cancer patients treated at our hospital were selected as research subjects. According to the random number table method, patients were divided into a control group (mFOLFOX6 plus bevacizumab) and a combination group (mFOLFOX6 plus bevacizumab after deep hyperthermia treatment), with 40 patients in each group. After six cycles of treatment, the objective response rate (ORR), disease control rate (DCR), levels of serum tumor markers carcinoembryonic antigen (CEA), vascular epidermal growth factor (VEGF), Karnofsky performance status (KPS) scores, and the occurrence of adverse events were compared between the two groups.ResultsAfter six cycles of treatment, the ORR in the combination group was higher than that in the control group, but the difference was not statistically significant (P>0.05). The DCR in the combination group was significantly higher than that in the control group (P<0.05). The serum CEA levels in the control and combination groups after treatment were significantly lower than those before treatment, and the serum CEA and VEGF levels in the combination group were significantly lower than those in the control group (all P<0.001). The KPS scores in both groups after treatment were higher than those before treatment, and the KPS scores in the combination group after treatment were significantly higher than those in the control group (all P<0.001). The incidence of fatigue and pain in the combination group was significantly lower than that in the control group (P<0.05).ConclusionmFOLFOX6 plus bevacizumab after deep hyperthermia is effective in advanced colorectal cancer patients, which can effectively improve their quality of life, and the adverse events are controllable and tolerable. A randomized or prospective trial will be required to further prove these data and explore its potentiality, especially if compared to conventional treatment.

show abstract

“…[148,[180][181][182] The ICD induced by PDT produces a vaccine-like function, converting the stimulated "cold" TME into immunogenic "hot" TME, which works in collaboration with ICB to initiate and activate CD8+ T cells to enhance the attack and killing of the cancer cells. [155,[183][184][185][186][187] The latest research indicates that combining PDT with ICB (such as PD-1/PD-L1 and IDO blockade) has become a promising clinical treatment, which can foster the immune system's killing ability against tumors, control the interaction between CTLs and immunosuppressive cells and ultimately prevent the growth of primary and metastatic lesions. [62,185,7,[188][189][190][191][192][193]…”

Section: T Cells Reprogramming (Related Immune Checkpoint Blockade)mentioning

confidence: 99%

Recent Advances in Reprogramming Strategy of Tumor Microenvironment for Rejuvenating Photosensitizers‐Mediated Photodynamic Therapy

Yu,

Li,

Wang

et al. 2023

Small

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has recently been considered a potential tumor therapy due to its time‐space specificity and non‐invasive advantages. PDT can not only directly kill tumor cells by using cytotoxic reactive oxygen species but also induce an anti‐tumor immune response by causing immunogenic cell death of tumor cells. Although it exhibits a promising prospect in treating tumors, there are still many problems to be solved in its practical application. Tumor hypoxia and immunosuppressive microenvironment seriously affect the efficacy of PDT. The hypoxic and immunosuppressive microenvironment is mainly due to the abnormal vascular matrix around the tumor, its abnormal metabolism, and the influence of various immunosuppressive‐related cells and their expressed molecules. Thus, reprogramming the tumor microenvironment (TME) is of great significance for rejuvenating PDT. This article reviews the latest strategies for rejuvenating PDT, from regulating tumor vascular matrix, interfering with tumor cell metabolism, and reprogramming immunosuppressive related cells and factors to reverse tumor hypoxia and immunosuppressive microenvironment. These strategies provide valuable information for a better understanding of the significance of TME in PDT and also guide the development of the next‐generation multifunctional nanoplatforms for PDT.

show abstract

Improved cancer immunotherapy strategies by nanomedicine

Cited by 8 publications

References 144 publications

Role of CD93 in Health and Disease

Role of CD93 in Health and Disease

Efficacy of mFOLFOX6 plus bevacizumab regimen in advanced colorectal cancer after deep hyperthermia: a single-center retrospective study

Recent Advances in Reprogramming Strategy of Tumor Microenvironment for Rejuvenating Photosensitizers‐Mediated Photodynamic Therapy

Contact Info

Product

Resources

About